Insiders Were the Key Beneficiaries as Zhejiang Tianyu Pharmaceutical Co., Ltd.'s (SZSE:300702) Market Cap Rises to CN¥6.3b
Insiders Were the Key Beneficiaries as Zhejiang Tianyu Pharmaceutical Co., Ltd.'s (SZSE:300702) Market Cap Rises to CN¥6.3b
Key Insights
关键洞察
- Zhejiang Tianyu Pharmaceutical's significant insider ownership suggests inherent interests in company's expansion
- A total of 2 investors have a majority stake in the company with 55% ownership
- 13% of Zhejiang Tianyu Pharmaceutical is held by Institutions
- 天宇股份的显著内部持股表明公司扩展的固有利益
- 共有2位投资者持有55%的大多数股份
- 13%的天宇股份由机构持有
To get a sense of who is truly in control of Zhejiang Tianyu Pharmaceutical Co., Ltd. (SZSE:300702), it is important to understand the ownership structure of the business. The group holding the most number of shares in the company, around 56% to be precise, is individual insiders. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).
要了解谁真正控制着天宇股份(SZSE:300702),理解该公司股权结构至关重要。持有公司最多股份的群体,大约56%,是个人内部人员。也就是说,如果股票上涨,这个群体将受益最多(如果出现下跌,他们将损失最多)。
As a result, insiders were the biggest beneficiaries of last week's 6.9% gain.
因此,内部投资者是上周6.9%涨幅的最大受益者。
In the chart below, we zoom in on the different ownership groups of Zhejiang Tianyu Pharmaceutical.
在下图中,我们聚焦于天宇股份的不同股东群体。
What Does The Institutional Ownership Tell Us About Zhejiang Tianyu Pharmaceutical?
机构持股告诉我们关于天宇股份的什么?
Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.
许多机构的表现与近似当地市场的指数进行比较。因此,他们通常更加关注那些被纳入主要指数的公司。
We can see that Zhejiang Tianyu Pharmaceutical does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Zhejiang Tianyu Pharmaceutical's earnings history below. Of course, the future is what really matters.
我们可以看到天宇股份确实有机构投资者,他们持有公司股权的相当一部分。这在专业投资者中暗示了一定的可信度。但我们不能仅仅依赖这一事实,因为机构有时也会做出糟糕的投资,就像其他人一样。如果多个机构在同一时间改变对某只股票的看法,股票价格可能会迅速下跌。因此,查看天宇股份的盈利历史是很有必要的。当然,未来才是真正重要的。
Zhejiang Tianyu Pharmaceutical is not owned by hedge funds. The company's largest shareholder is Jie Lin, with ownership of 35%. Yong Jun Tu is the second largest shareholder owning 20% of common stock, and Jiangsu Zhaoxin Private Fund Management Co., Ltd. holds about 6.3% of the company stock. Yong Jun Tu, who is the second-largest shareholder, also happens to hold the title of Chief Executive Officer.
天宇股份不被对冲基金持有。公司的最大股东是林杰,持股比例为35%。冯俊图是第二大股东,持有20%的普通股,江苏兆信私募基金管理有限公司持有大约6.3%的公司股票。冯俊图作为第二大股东,同时也担任首席执行官。
A more detailed study of the shareholder registry showed us that 2 of the top shareholders have a considerable amount of ownership in the company, via their 55% stake.
对股东登记册的更详细研究表明,前两大股东通过其55%的股份在公司中拥有相当可观的股份。
While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There is some analyst coverage of the stock, but it could still become more well known, with time.
尽管研究公司的机构持股可以为您的研究增加价值,但研究分析师的建议也是一个好习惯,以更深入地了解股票的预期表现。该股票有一些分析师覆盖,但随着时间的推移,它仍然可能变得更加知名。
Insider Ownership Of Zhejiang Tianyu Pharmaceutical
天宇股份的内部持股情况
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
虽然对内部人的确切定义可能是主观的,但几乎每个人都认为董事会成员是内部人。公司管理层运行业务,但CEO会向董事会报告,即使他或她是董事会成员。
Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.
当内部持股显示领导层像真正的公司所有者一样思考时,这是积极的。然而,高比例的内部持股也可能给予公司内部小团体巨大的权力。在某些情况下,这可能是负面的。
Our information suggests that insiders own more than half of Zhejiang Tianyu Pharmaceutical Co., Ltd.. This gives them effective control of the company. So they have a CN¥3.5b stake in this CN¥6.3b business. It is good to see this level of investment. You can check here to see if those insiders have been buying recently.
我们的信息显示,内部人士持有天宇股份超过一半的股份。这使他们有效地控制了公司。因此,他们在这个63亿人民币的业务中持有35亿人民币的股份。看到这样的投资水平是不错的。你可以在这里查看这些内部人士最近是否在购买。
General Public Ownership
公众持股
The general public, who are usually individual investors, hold a 30% stake in Zhejiang Tianyu Pharmaceutical. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.
公众,一般是个人投资者,在天宇股份中持有30%的股份。虽然这种规模的持有可能不足以影响政策决策,但他们仍然可以对公司的政策产生集体影响。
Next Steps:
下一步:
It's always worth thinking about the different groups who own shares in a company. But to understand Zhejiang Tianyu Pharmaceutical better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 1 warning sign with Zhejiang Tianyu Pharmaceutical , and understanding them should be part of your investment process.
思考拥有公司股票的不同群体总是值得的。但要更好地了解天宇股份,我们需要考虑许多其他因素。 例如,时刻存在的投资风险。 我们已经发现天宇股份的一个警示信号,理解这些信号应该是您投资过程的一部分。
If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.
如果您想了解分析师对未来增长的预测,请不要错过这份关于分析师预测的免费报告。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注意:本文中的数字是根据过去十二个月的数据计算得出的,指的是截至财务报表日期的月份最后一天的12个月期间。这可能与完整年度的年报数字不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有反馈?对内容有疑虑?请直接与我们联系。或者,发送电子邮件至 editorial-team (at) simplywallst.com。
这篇来自Simply Wall St的文章是一般性的。我们根据历史数据和分析师预测提供评论,采用无偏见的方法,我们的文章并不旨在提供财务建议。它不构成对任何股票的买入或卖出建议,也未考虑到您的目标或财务状况。我们旨在为您提供以基本数据驱动的长期分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St在提到的任何股票中均没有持仓。